source
- Moderna’s stock soars after Phase 3 success of melanoma vaccine with MerckBioPharma Dive’s latest data-visualization series charts Moderna’s dramatic stock rebound in 2026 after a period of decline. The company had struggled when demand for its COVID-19 vaccine fell, pr…
- Hospitals Turn to Longevity Clinics as New Revenue StreamSTAT's biotech podcast "The Readout LOUD" featured a discussion about the rapid growth of longevity clinics that are being opened by hospitals. Reporters noted that the longevity medicine market i…